RxDoctor Payments Data

Beth Monsebroten

Family · Hot Springs, SDNPI 1336495407

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 61.6% of it on its own, with 17 other manufacturers making up the rest. Among family clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,414in general payments, 2019–2025

Across 132 payments — averaging $33.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$315
  • Harmony Biosciences LLC$179
  • Sanofi$160
  • Verona Pharma, Inc.$123
  • Boehringer Ingelheim$113
  • plus $808 from 12 others

What the payments were for

  • Food & beverage$4,17094%
  • Education$2446%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,414 in reported general payments places this provider in the 95th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter483$342,521
Breztri AerosphereBudesonide/Glycopyr/Formoterol180$120,683
Spiriva RespimatTiotropium Bromide45$30,403
Combivent RespimatIpratropium/Albuterol Sulfate37$18,781
Spiriva HandihalerTiotropium Bromide37$18,648
Breo ElliptaFluticasone/Vilanterol36$15,315
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$11,049
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,527
SymbicortBudesonide/Formoterol Fumarate31$8,680
Albuterol Sulfate HfaAlbuterol Sulfate248$7,815
Incruse ElliptaUmeclidinium Bromide18$7,551
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate43$7,285
Ventolin HfaAlbuterol Sulfate121$7,028
DuleraMometasone/Formoterol17$6,083
Fluticasone-SalmeterolFluticasone Propion/Salmeterol57$6,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$315$374,912557 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,717$129,363211 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$113$60,23399 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family providers in South Dakota.

Other family in Hot Springs

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →